More treatment options. Transparent pricing. A new way for employers to put obesity care within reach.

NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Andel, the direct-to-employer medication marketplace, today announced a collaboration with Novo to bring Wegovy® to its employer network, including the once-daily Wegovy® pill and Wegovy® HD, both of which launched earlier in 2026. The collaboration brings more choice in obesity treatment with a simpler way for employers to help employees pay for it.

Employers choose how much to contribute toward treatment, reducing employees' out-of-pocket costs while retaining control over their spending. Andel coordinates the experience from prescription verification to delivery through its app.

"Andel enables employers to pay for critical prescriptions seamlessly and without insurance friction," said Jay Bregman, Founder and CEO of Andel. "Employers want to help staff get well, but they need control over the bill and a beautiful member experience powered by native apps and Andel's digital pharmacy platform."

"Expanding access means removing barriers and making it easier for people to take the next step toward acquiring the treatment they need," said Tom Scales, Senior Vice President, Market Access and Public Affairs at Novo. "Our collaboration with Andel creates another way for employers to support that step. Through this partnership we can help more eligible people access the treatment they need in consultation with their healthcare professional."

For employers facing rising medication expenses, Andel offers a practical way to support access outside traditional pharmacy benefits. Large companies, small businesses, and startups can choose a contribution that fits their budgets while giving employees access to manufacturer-direct pricing across Andel's growing medication platform.

Companies interested in bringing Andel to their employees can learn more at andel.org.

About Andel

Andel is a cooperative marketplace connecting employers and pharmaceutical manufacturers that operates using tax-free dollars rather than insurance. The platform combines direct manufacturer pricing, employer contributions, and a simple member experience. It works alongside existing benefits, lets members keep their doctors, and coordinates prescription fulfillment and delivery. The company is backed by $4.5 million in initial venture funding from top investors. Andel Pharmacy, LLC is a licensed pharmacy. Learn more at: https://www.andel.org/press.

The Andel Discount Drug Program is NOT insurance. The Andel Discount Drug Program offers reduced prices from participating providers, and discounts vary by provider and service. Participants are responsible for paying discounted charges, as the Andel Discount Drug Program does not make payments to providers on participants' behalf. Discounts are available only from providers who have contracted to be in network. For more information and a list of participating providers, please contact us at [email protected], or by calling us at (833) 962 6335.

Media Contact:

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/andel-collaborates-with-novo-to-bring-wegovy-injection-and-wegovy-pill-direct-to-employers-302921477.html

SOURCE Andel Co-op, Inc.